Combined use of fractional exhaled nitric oxide and bronchodilator response in predicting future loss of asthma control among children with atopic asthma

Respirology

Volumn 22, Issue 3, 2017, Pages 466-472

  Kim, Je Kyung ^a   Jung, Jae Yub ^a   Kim, Heon ^b   Eom, Sang Yong ^b   Hahn, Youn Soo ^a  

^a Chungbuk National University   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

Author keywords

asthma; atopy; bronchodilator response; child; fractional exhaled nitric oxide; loss of asthma control

Indexed keywords

BRONCHODILATING AGENT; NITRIC OXIDE;

ADOLESCENT; ALLERGIC ASTHMA; ARTICLE; BRONCHODILATOR RESPONSE; CHILD; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; FORCED EXPIRATORY VOLUME; FRACTIONAL EXHALED NITRIC OXIDE; HIGH RISK PATIENT; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PATIENT MONITORING; PREDICTION; PROGNOSIS; RISK ASSESSMENT; ASTHMA; BREATH ANALYSIS; BRONCHUS; COMPLICATION; DISEASE EXACERBATION; DRUG EFFECTS; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE;

ASTHMA; BREATH TESTS; BRONCHI; BRONCHODILATOR AGENTS; CHILD; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MALE; NITRIC OXIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 85002406498     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12934     Document Type: Article

References (30)

1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733–43.
2. Forno E, Celedon JC. Predicting asthma exacerbations in children. Curr. Opin. Pulm. Med. 2012; 18: 63–9.
3. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180: 59–99.
4. Taylor DR, Pijnenburg MW, Smith AD, Jongste JCD. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006; 61: 817–27.
5. Zeiger RS, Schatz M, Zhang F, Crawford WM, Kaplan MS, Roth RM, Chen W. Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J. Allergy Clin. Immunol. 2011; 128: 412–4.
6. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, Taylor DR. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am. J. Respir. Crit. Care Med. 2001; 164: 738–43.
7. Yang S, Park J, Lee YK, Kim H, Hahn YS. Association of longitudinal fractional exhaled nitric oxide measurements with asthma control in atopic children. Respir. Med. 2015; 109: 572–9.
8. Stern G, de Jongste J, van der Valk R, Baraldi E, Carraro S, Thamrin C, Frey U. Fluctuation phenotyping based on dailyfraction of exhaled nitric oxide values in asthmatic children. J. Allergy Clin. Immunol. 2011; 128: 293–300.
9. van der Valk RJ, Baraldi E, Stern G, Frey U, de Jongste JC. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy 2012; 67: 265–71.
10. Kerstjens HA, Brand PL, Quanjer PH, van der Bruggen-Bogaarts BA, Koeter GH, Postma DS. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax 1993; 48: 722–9.
11. Fingleton J, Weatherall M, Beasley R. Bronchodilator responsiveness: interpret with caution. Thorax 2012; 67: 667–8.
12. Sharma S, Litonjua AA, Tantisira KG, Fuhlbrigge AL, Szefler SJ, Strunk RC, Zeiger RS, Murphy AJ, Weiss ST. Clinical predictors and outcomes of consistent bronchodilator response in childhood asthma management program. J. Allergy Clin. Immunol. 2008; 122: 921–8.
13. Galant SP, Morphew T, Newcomb RL, Hioe K, Guijon O, Liao O. The relationship of the bronchodilator response phenotype to poor asthma control in children with normal spirometry. J. Pediatr. 2011; 158: 953–9.
14. Tantisira KG, Fuhlbrigge AL, Tonascia J, Van Natta M, Zeiger RS, Strunk RC, Szefler SJ, Weiss ST. Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma. J. Allergy Clin. Immunol. 2006; 117: 1264–71.
15. Postma Da DVK, Koeter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am. Rev. Respir. Dis. 1986; 134: 276–80.
16. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full Report 2007. [Accessed 22 Feb 2010.] Available from URL: http://www.nhlbi.nih.gov/about/naepp/index.htm
17. Juniper EF, Bousquet J, Abetz L, Bateman ED GOAL Committee. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir. Med. 2006; 100: 616–21.
18. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 2005; 171: 912–30.
19. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten C, Gustafsson P et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319–38.
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am. J. Respir. Crit. Care Med. 1999; 159: 179–87.
21. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26: 948–68.
22. Tse SM, Gold DR, Sordillo JE, Hoffman EB, Gillman MW, Rifas-Shiman SL, Fuhlbrigge AL, Tantisira KG, Weiss ST, Litonjua AA. Diagnostic accuracy of the bronchodilator response in children. J. Allergy Clin. Immunol. 2013; 132: 554–9.
23. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 2005; 115: 233–42.
24. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N. Engl. J. Med. 2010; 362: 975–85.
25. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med. 2011; 184: 602–15.
26. Faul JL, Demers EA, Burke CM, Puulter LW. Alterations in airway inflammation and lung function during corticosteroid therapy for atopic asthma. Chest 2002; 121: 1414–20.
27. Dixon AE, Irvin CG. Early intervention of therapy in asthma. Curr. Opin. Pulm. Med. 2005; 11: 51–5.
28. Djukanovic R. Airway inflammation in asthma and its consequences: implications for treatment in children and adults. J. Allergy Clin. Immunol. 2002; 109: S539–48.
29. Goleva E, Hauk PJ, Boguniewicz J, Martin RJ, Leung DY. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J. Allergy Clin. Immunol. 2007; 120: 1065–72.
30. Portney LG, Watkins MP. Foundations of Clinical Research: Applications to Practice. Cranbury, NJ, Pearson Education, 2009.